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Abstract
Background: Geographic and sociodemographic characterization of hepatitis C virus (HCV) transmission amongst
men who have sex with men (MSM) has been limited. Our aim was to characterize HCV prevalence, risk factors for
HCV co-infection, and patterns of HIV and HCV co-transmission and transmitted drug resistance mutations (DRMs)
in newly HIV-diagnosed Los Angeles MSM.
Methods: Viral RNA was extracted from stored plasma samples from a Los Angeles cohort of newly diagnosed HIV-
infected MSM with well-characterized substance use and sexual behavioral characteristics via computer-assisted self-
interviewing surveys. Samples were screened for HCV by qPCR. HCV E1, E2, core,
NS3 protease and NS5B polymerase and HIV-1 protease and reverse transcriptase regions were amplified and
sequenced. Phylogenetic analysis was used to determine relatedness of HCV and HIV-1 isolates within the cohort
and viral sequences were examined for DRMs.
Results: Of 185 newly HIV-diagnosed MSM, the majority (65 %) were of minority race/ethnicity and recently infected
(57.8 %), with median age of 28.3 years. A minority (6.6 %) reported injection drug use (IDU), whereas 96 (52.8 %)
reported recent substance use, primarily cannabis or stimulant use. High risk sexual behaviors included 132 (74.6 %)
with unprotected receptive anal intercourse, 60 (33.3 %) with group sex, and 10 (5.7 %) with fisting. Forty-five (24.3 %)
had acute gonorrhea or chlamydia infection. Only 3 (1.6 %) subjects had detectable HCV RNA. Amongst these subjects,
HIV and HCV isolates were unrelated by phylogenetic analysis and none possessed clinically relevant NS3 or NS5B HCV
DRMs.
Conclusions: Prevalence of HCV co-infection was low and there was no evidence of HIV-HCV co-transmission in this
cohort of relatively young, predominantly minority, newly HIV-diagnosed MSM, most with early HIV infection, with high
rates of high risk sexual behaviors, STI, and non-IDU. The low HCV prevalence in a group with high-risk behaviors for
non-IDU HCV acquisition suggests an opportune time for targeted HCV prevention measures.
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Background
Hepatitis C virus (HCV) co-infection is common amongst
HIV-infected persons, affecting an estimated 4 to 5 mil-
lion persons worldwide, and is associated with increased
morbidity and mortality [1, 2]. Whereas the primary
route of HCV transmission remains injection drug use
(IDU), over recent years there has been increasing evi-
dence of sexual transmission among HIV-infected men
who have sex with men (MSM), likely driven by mu-
cosal risk factors, including unprotected and traumatic
sexual practices in the context of multiple partners, non-
injection drug use, and sexually transmitted infections
[3–7]. Prevalence estimates for HCV co-infection in
HIV-infected MSM have ranged from 6 to 15.7 %, with
limited geographic characterization [8–12]. The preva-
lence of HCV co-infection in HIV-infected MSM in Los
Angeles County (LAC) in the U.S. has not been defined,
despite LAC being the second largest epicenter for AIDS
cases nationally, with high rates of non-injection drug
use and high-risk sexual practices. Our aims were to
characterize the prevalence of and risk factors for
HCV co-infection and patterns of HIV and HCV co-trans-
mission and drug resistance mutations (DRMs) in a
cohort of newly HIV-infected or HIV-diagnosed Los
Angeles MSM.
Methods
Between February 2009 and May 2012 we enrolled par-
ticipants from a community-based organization provid-
ing sexual health services to the gay community in LAC:
The Los Angeles LGBT Center. Clients were eligible if
they were recently HIV-infected (<1 year of infection) or
newly HIV-diagnosed, at least 18 years of age, male, and
reported sex with a male partner in the past year. Recent
infection was determined by one of four ways: nucleic
acid amplification test with negative serology, detuned
assay (Low Sensitivity Vitros ECi, Ortho Clinical Diag-
nostics, Rochester, NY), provider verification, or negative
HIV testing within the past year. Plasma was collected
and syphilis, chlamydia, and gonorrhea testing performed
for all participants. Behavioral and sociodemographic data
were collected via computer-assisted self-interview. Mi-
nority race/ethnicity was defined as self-identified
African-American race or Hispanic ethnicity.
Viral RNA was extracted from stored plasma using the
UltrasSens Viral Isolation kit (Qiagen), converted to
cDNA using Superscript III Reverse Transcriptase (Invi-
trogen), and screened for HCV by quantitative polymerase
chain reaction (PCR) designed to detect the HCV 5′UTR.
The HCV E1/E2/core, NS3 and NS5B regions from HCV
positive samples and HIV-1 protease and RT regions from
all samples were amplified using either Phusion High-
Fidelity DNA Polymerase (New England BioLabs) or KOD
High-Fidelity Polymerase (Novagen). PCR products were
directly sequenced using the BigDye v3.1 Kit (Applied
Biosystems).
Sequences were checked for quality, edited, and align-
ments performed using Chromas Lite (Technelysium Pty
Ltd, South Brisbane, Australia) and BioEdit (Ibis Biosci-
ences, Carlsbad, CA). Consensus sequences of an 857
nucleotide (nt) fragment of the HCV NS3 protease gene
spanning amino acids 13–297 were aligned with genotype
consensus sequences obtained from the Los Alamos Na-
tional Laboratory (LANL) HCV database (http://www.hiv.
lanl.gov), JFH-1, and additional HCV sequences collected
from the Los Angeles area. A 1302 nt fragment of the pol
gene (HXB2 reference location nt 2254–3555) was aligned
with the Clade B consensus sequences obtained from the
LANL HIV database. Neighbor-joining phylogenetic trees
were generated using the DNAdist and Neighbor programs
of PHYLIP. Sequences were examined for the follow-
ing HCV DRMs: V36M/A, T54A/S, V55A, Q80K, R155K,
A156S/T, D168T/V, I/V170A and S282T. HIV-1 DRMs
were determined using the Stanford University HIV Drug
Resistance Database (http://hivdb.stanford.edu/).
The study was reviewed and approved by the Univer-
sity of California, Los Angeles Institutional Review Board
(IRB# 10–000806) and the Los Angeles LGBT Center Re-
view Committee. Written informed consent was obtained
from each study participant, including permission to use
stored plasma samples for research testing.
Results
One hundred eight-five subjects were included in this
study. Sociodemographic, behavioral, and clinical char-
acteristics are summarized in Table 1. Median age (inter-
quartile range, IQR) was 28.3 (24.7–35.0 years) and the
majority were of minority race or ethnicity (66.9 %) and
recently HIV-infected (57.8 %). At the time of plasma col-
lection, 24 (13.7 %) reported being prescribed antiretro-
viral therapy (ART). Median number of partners within
the past 12 months was 9 (IQR 4–20), with unprotected
receptive or insertive anal intercourse (URAI or UIAI)
reported by 132 (74.6 %) and 115 (64.6 %), respectively.
Forty-five (24.3 %) subjects tested positive for gonorrhea
or chlamydia, with 47 (27.5 %) testing positive for syphilis
at baseline. A minority (6.6 %) reported IDU in the past
12 months, whereas 96 (52.8 %) reported recent substance
use, primarily cannabis or stimulant use.
Only 3 (1.6 %) subjects had detectable HCV RNA. HCV
viral load ranged from 67,000 to 2.2 million copies/ml.
There were too few HCV infections to identify significant
risk factors for HCV co-infection. Of the 3 HCV-positive
subjects, all were of minority race or ethnicity; one subject
was classified as newly HIV infected by detuned assay
and two were newly diagnosed with HIV infection of
unknown duration. Only 1 reported a history of IDU.
All 3 subjects reported non-injection drug use, including
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methamphetamines, within the past 3 months. All 3 sub-
jects also reported high-risk sexual behavior, including
UIAI, URAI, and group sex.
Amongst the 3 HCV-infected subjects (subjects A, B,
and C), HIV and HCV sequences were unrelated by
phylogenetic analysis (see Fig. 1). Based on HCV NS3
Table 1 Baseline characteristics of the cohort, overall and by hepatitis C virus (HCV) status
Characteristic Total (N = 185) na (%)
or median (IQR)
HCV negative (N = 182) na (%)
or median (IQR)
HCV positive (N = 3) na (%)
or median (IQR)
Sociodemographics
Age (years) 28.3 (24.7–35.0) 28.3 (24.7–34.8) 35.8 (22.3–45.1)
Race
African American 32 (17.7) 31 (17.4) 1 (33.3)
Hispanic 89 (49.2) 87 (48.9) 2 (66.7)
White 47 (26.0) 47 (26.4) 0 (0)
Asian 5 (2.8) 5 (2.8) 0 (0)
Other 8 (4.4) 8 (4.4) 0 (0)
Incarcerated, past 12 months 17 (9.3) 17 (9.5) 0 (0)
Substance Use, past 3 months
Any drugs (including cannabis) 96 (52.8) 93 (52.0) 3 (100)
Cannabis 79 (43.4) 77 (43.0) 2 (66.7)
Cocaine 26 (14.3) 25 (14.0) 1 (33.3)
Methamphetamine 33 (18.1) 30 (16.8) 3 (100)
Inhalants 6 (3.3) 5 (2.8) 1 (33.3)
Sedatives 16 (8.8) 15 (8.4) 1 (33.3)
Hallucinogens 3 (1.7) 2 (1.1) 1 (33.3)
Opioids 6 (3.3) 5 (2.8) 1 (33.3)
Injection drug use, past 12 months 12 (6.6) 11 (6.2) 1 (33.3)
Partner injection drug use, past 12 months 34 (18.6) 32 (17.8) 2 (66.7)
Alcohol use, past 3 months 129 (70.9) 127 (71.0) 2 (66.7)
Sexual Behaviors
Sexual partners, past 12 months 9 (4–20) 9 (4–20) 6 (6–14)
Unprotected insertive AI, last 6 partners 115 (64.6) 113 (64.2) 2 (66.7)
Unprotected receptive AI, last 6 partners 132 (74.6) 130 (74.3) 2 (66.7)
Fisted by partner, last 6 partners 10 (5.7) 10 (5.8) 0 (0)
Transactional sex 20 (11.0) 19 (10.6) 1 (33.3)
Group sex 60 (33.3) 58 (32.4) 2 (66.7)
Sexually Transmitted Infections
Chlamydia, baseline testing 32 (18.2) 30 (17.3) 2 (66.7)
Gonorrhea, baseline testing 19 (10.6) 19 (10.8) 0 (0)
Syphilis, TPPA positive, baseline testing 47 (27.5) 46 (27.2) 1 (33.3)
Chlamydia, self-reported, past 12 months 69 (37.9) 68 (38.0) 1 (33.3)
Gonorrhea, self-reported, past 12 months 65 (35.7) 64 (35.8) 1 (33.3)
Syphilis, self-reported, past 12 months 57 (31.3) 56 (31.3) 1 (33.3)
HSV, self-reported, past 12 months 11 (6.0) 11 (6.2) 0 (0)
HIV viral load, copies/mLb 41,538 (5771–150,756) 41,518 (6296–144,378) 60,476 (<50–155,000)
CD4 cell count (cells/mm3)c 553 (408–692) 553 (408–692) Unavailable
IQR interquartile range, AI anal intercourse, TPPA treponema pallidum particle agglutination, HSV herpes simplex virus
aSum of n may not equal total N because of missing data; bAvailable for 171 of 185 subjects; cAvailable for 80 subjects
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protease sequences, a neighbor-joining phylogenetic tree
showed that HCV sequences from subjects A and C
were most closely related to genotype 1a; and subject B,
to genotype 3a. The two genotype 1a-infected subjects
had sequences that were no more closely related to each
other than to other isolates from the Los Angeles area,
indicating that these were not a closely linked transmis-
sion pair. Similar results were obtained using a 1784 nt
fragment of HCV NS5B and a 2470 nt fragment span-
ning the E1-E2-Core region of the genome (data not
shown). No HIV-1 sequence was obtained from HCV-
positive subject A, who was identified at screening as
having recently acquired HIV infection, but had initiated
antiretroviral therapy with fully suppressed HIV viremia
at the time of study enrollment and plasma collection.
HIV-1 sequences from subjects B and C were no more
closely related to each other than to sequences obtained
from other cohort members. However, the HIV-1 se-
quences from subject C and another subject (D) were
closely related with 100 % bootstrap support and an
inter-patient genetic distance of <1 % strongly indicative
of these being a transmission pair. Subject D was HCV-
negative, both by qPCR and serologically. One subject,
who was ART naïve, had an HIV RT mutation (K103N).
None had clinically relevant NS3 or NS5B HCV DRMs.
Discussion
Prevalence of HCV co-infection was low and there was
no evidence of HIV-HCV co-transmission in this cohort
of young, predominantly minority, newly HIV-diagnosed
MSM. The majority of subjects had recent HIV infection
and notable behavioral and clinical risk factors for sexual
HCV transmission, including high-risk sexual practices,
sexually transmitted infections, and non-injection (pri-
marily stimulant) substance use, with low rates of injec-
tion drug use. The lower prevalence of HCV compared
with other HIV-infected MSM cohorts (1.6 vs 6–15.7 %)
[8–12] may reflect the younger age of the cohort with
fewer cumulative exposures to HCV, lower rates of IDU,
relatively greater immune preservation with earlier HIV
infection, and identification of HCV by HCV RNA instead
of by serology. In our study, by measuring HCV RNA, we
measured prevalence of active HCV replication and not
exposure or infection with possible clearance, as would be
measured by serology. Assessment by both serology and
HCV RNA would provide broader characterization of
HCV exposure in the cohort, but due to limited sample
volume, we could not perform testing for both and elected
for HCV RNA testing alone as a measure of active HCV
infection and risk for HCV transmission. Demograph-
ically, our cohort differed from others in its geographic
and racial/ethnic composition, wherein our cohort was
predominantly of minority race and half was Hispanic,
as compared to most other reported cohorts that were
Fig. 1 a Phylogenetic analysis of Hepatitis C virus (HCV) isolates.
Consensus sequences of an 857 nucleotide (nt) fragment of the HCV
NS3 protease from the three HCV isolates from the cohort were
aligned with the Los Alamos National Laboratory HCV Database
consensus sequences for HCV genotype (gt) 1a and 3a, along with
additional reference sequences from subjects living in Los Angeles, to
make a neighbor-joining tree. The consensus sequences for gt 1a and
3a are labeled as “CON” with the corresponding genotype. The Los
Angeles HCV sequences are labeled as “LA” with the corresponding
subject number. The HCV-positive subject samples are labeled A, B,
and C. The tree is rooted with the HCV genotype 1a consensus se-
quence and the genetic distance scale bar is located at the center of
the figure. b Phylogenetic analysis of HIV-1 pol. A 1302 nt fragment of
pol covering the HIV-1 protease and reverse transcriptase (HXB2 refer-
ence location nt 2254–3555) from
N = 148 isolates from the cohort was aligned with the Clade B consen-
sus and used to build a neighbor-joining tree. Each
sequence is labeled with a unique subject identifier, and the HCV-
positive subjects are labeled A, B, and C. The tree is rooted with the
Clade B consensus sequence. The genetic distance scale bar is located
at the lower left of the figure
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predominantly White. The epidemiology of HCV co-
infection in HIV-infected Hispanic MSM has not been
well described. As described by Kunikholm et al., util-
izing National Health and Nutrition Examination Survey
(NHANES) and Hispanic Community Health Study/Study
of Latinos (HCHS/SOL) data, HCV prevalence appears to
differ by Hispanic/Latino background and the prevalence
of HCV in the West Coast Hispanic population may be
lower than in others [13].
While there were too few subjects with HCV infection
in the cohort to explore associations between potential
behavioral risk factors and HCV infection, the subjects
that did have HCV co-infection all reported metham-
phetamine and other non-injection drug use, as well as
high-risk sexual practices, consistent with risk factors
identified in larger cohorts. The lack of HCV clustering
or transmission pairs is likely due to the smaller sample
size than in other studies [6, 7], as well as may relate
uniquely to the geographically wide sexual networks in
LAC compared to other urban areas. The lack of evidence
of HIV-HCV co-transmission may reflect the low preva-
lence of HCV infection in the cohort, but may also suggest
that co-transmission occurs infrequently, and that HCV
infection is more often acquired following HIV infection,
instead of simultaneously or preceding HIV infection, par-
ticularly in non-IDU settings. The lack of HCV DRMs is
likely due to the few observed HCV infections.
Conclusions
We found a lower than expected prevalence of HCV
infection in our LAC HIV-infected cohort of MSM.
By behavioral risk factors, the population studied is at
high risk for incident HCV infection. This presents an
opportunity, namely at the time of a new HIV diagnosis
and during early HIV infection, for targeted HCV preven-
tion strategies to reduce non-IDU HCV transmission
among HIV-infected MSM.
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